Standardized Shorter MDR-TB Regimen (SSR)
Treatment for Multidrug-resistant tuberculosis without extensive drug resistance
Typical Dosage: Standard regimen including Moxifloxacin, Ethionamide, Pyrazinamide, Ethambutol, Clofazimine, and an injectable for 4-6 months
Effectiveness
75%
Safety Score
48%
Clinical Trials
20
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
48
DangerousModerateSafe
Treatment Details
Dosage Range
Standard regimen including Moxifloxacin, Ethionamide, Pyrazinamide, Ethambutol, Clofazimine, and an injectable for 4-6 months
Time to Effect
1-2 months for culture conversion
Treatment Duration
9-12 months
Evidence Quality
MODERATEConfidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$8,000
Monitoring:$4,000
Side Effect Mgmt:$3,000
Total Annual:$15,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$60,000/QALY
QALYs Gained
0.5
Outcome-Based Costs
Cost per Responder
$19,231
Cost per Remission
$20,548
Comparison vs Conventional longer injectable MDR-TB regimen
Cost Difference
$-3,000/year
Less expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Standardized Shorter MDR-TB Regimen (SSR) Outcomes
for Multidrug-resistant tuberculosis without extensive drug resistance
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+78%
Remission Rate
+73%
Common Side Effects
Hearing loss/vestibular toxicity (injectables)
+25%
Nephrotoxicity (injectables)
+12%
Gastrointestinal intolerance
+45%
QT prolongation
+20%
Hypothyroidism
+10%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov